FDA Approves Mannkind's Afrezza - a Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes

MannKind Corporation has announced that FDA has approved Afrezza (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus.

"Approval of Afrezza is an important milestone for MannKind, as today's (27 June) FDA action validates the years of clinical research and commitment that powered the development of this unique therapy," said Alfred Mann, Chief Executive Officer, MannKind Corporation. "We are excited for patients, as we believe that Afrezza's distinct profile and non-injectable administration will address many of their unmet needs for mealtime insulin therapy, and has the potential to change the way that diabetes is treated. We thank the more than 6500 adult patients and healthy volunteers who participated in the Afrezza clinical programme."

Afrezza is a novel, rapid-acting inhaled insulin therapy indicated to improve glycemic control in adult patients with diabetes mellitus. The product consists of Afrezza Inhalation Powder delivered using a small, discreet and easy-to-use inhaler. Administered at the start of a meal, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12–15 minutes of administration, and decline to baseline by approximately 180 minutes.

"The FDA approval of Afrezza provides healthcare professionals with an important new safe and effective treatment option for patients with diabetes," said Janet McGill, MD, Professor of Medicine at Washington University School of Medicine. "We have seen in clinical studies that the combination of rapid action, injection-free delivery and ease of use makes Afrezza a welcome alternative for many patients who require insulin."